Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome
patients that have a first line chemotherapy treatment failure due to refractoriness, partial
response or relapsed.
In the same way, mortality, global survival and free-progression survival after O-ESHAP
treatment and TAPH will also analyzed.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea